GLP-1 peptides and the muscle loss problem

The rapid weight loss produced by semaglutide, tirzepatide, and the emerging triple-agonist retatrutide has generated a familiar cycle of concern in the metabolic health community. People lose weight quickly. People notice that some of that weight is muscle. A narrative forms that these drugs are “eating away at lean tissue,” carrying the implication that GLP-1 receptor agonists cause a uniquely catabolic state that other weight loss approaches do not. The body composition data from the STEP and SURMOUNT trials tell a more measured story that is worth understanding in full before drawing conclusions, because the difference between proportionate lean mass loss and disproportionate lean mass loss is the difference between a predictable metabolic adaptation and a drug-specific concern that would demand a different clinical calculus.

I · Why rapid weight loss and lean mass loss travel together

The concern about muscle loss on GLP-1 receptor agonists did not emerge from a specific signal in the clinical trial data. It emerged from a well-established principle of energy metabolism that predates these drugs by decades. When the body enters a sustained caloric deficit, it does not selectively oxidize adipose tissue because adipose tissue is not the only tissue that costs energy to maintain. Skeletal muscle is metabolically expensive, consuming roughly 13 kcal per kilogram per day at rest, and when energy intake drops sharply, the body responds by reducing the amount of tissue it has to support. This is an adaptive mechanism, not a pathological one, and it is the same mechanism that produces lean mass loss during dietary restriction, bariatric surgery, and any other intervention that creates a large and sustained energy deficit.²

Dr. Kyle Gillett, a dual-board-certified physician in obesity medicine and family medicine who has published on body composition optimization during weight loss, has described the lean mass loss phenomenon as a predictable consequence of the rate and magnitude of weight loss rather than a property of any specific drug. His framework distinguishes between the proportion of lean mass lost, which is determined primarily by the size of the caloric deficit and the protein intake during the deficit, and the functional consequences of that loss, which are determined by whether the lost muscle is replaced or whether it represents a net decline in functional capacity over time.³

The concern becomes clinically relevant when the rate of weight loss exceeds roughly 1% of body weight per week, because at that rate the body’s capacity to preferentially mobilize fat is exceeded and the proportion of lean mass in the total weight lost begins to increase. Semaglutide 2.4 mg, the dose used in the STEP trials, produces weight loss of approximately 0.8% to 1.2% of body weight per week during the active weight loss phase, which places it squarely in the range where lean mass loss becomes a meaningful variable.⁴

II · What the STEP and SURMOUNT trials actually show about body composition

The STEP 1 trial, published by Dr. John Wilding and colleagues in the New England Journal of Medicine in 2021, was the central Phase III study that established semaglutide 2.4 mg as a weight management therapy. Among the 140 participants who underwent DEXA scanning in a prespecified substudy, those receiving semaglutide lost a mean of 15.2 kg of total body weight over 68 weeks, of which 10.4 kg was fat mass and 5.0 kg was lean mass. The proportion of lean mass in the total weight lost was approximately 33%, which is within the expected range for weight loss of this magnitude achieved through lifestyle intervention alone.⁵

The SURMOUNT-1 trial, led by Dr. Ania Jastreboff of Yale University and published in the New England Journal of Medicine in 2022, was the central Phase III study for tirzepatide. The body composition analysis from this trial, performed on a subset of 255 participants, showed that tirzepatide 15 mg produced a mean total weight loss of 17.8 kg over 72 weeks, with lean mass loss accounting for approximately 30% to 35% of the total. Dr. Jastreboff and her co-authors noted that the proportion of lean mass lost was consistent with the expected contribution of lean mass to total weight loss at this magnitude and did not indicate a drug-specific effect on muscle catabolism.⁶

Jastreboff et al., New England Journal of Medicine, 2022

The body composition data from SURMOUNT-1 also revealed a finding that has been under-discussed in the muscle loss conversation. The ratio of lean mass loss to total weight loss did not worsen as the tirzepatide dose increased from 5 mg to 15 mg, even though total weight loss increased substantially across the dose range. If tirzepatide were causing disproportionate muscle loss through a drug-specific mechanism, the proportion of lean mass in the total weight lost would be expected to increase with dose. The fact that it did not suggests that the lean mass loss is driven by the magnitude of the energy deficit rather than by a direct catabolic effect of the drug on muscle tissue.⁷

III · Why muscle loss matters beyond the number on the scale

The clinical reason to care about muscle loss during weight reduction is not that the scale rewards you for preserving muscle. It is that skeletal muscle is the body’s largest glucose sink, responsible for approximately 80% of postprandial glucose disposal through insulin-stimulated GLUT4 translocation, and the loss of muscle mass reduces this disposal capacity. This creates a metabolic irony: the very intervention that improves insulin sensitivity through fat loss can simultaneously reduce total glucose disposal capacity through muscle loss, which means the net effect on metabolic health depends on the ratio of fat loss to muscle loss and on whether the preserved muscle remains insulin-sensitive.⁸

Dr. Trevor Bachmeyer, a researcher and clinician who has published on body composition optimization during pharmacological weight loss, has emphasized that the functional significance of lean mass loss depends less on the absolute kilograms lost and more on whether the loss occurs preferentially from the muscle groups that matter most for metabolic health and physical function. His research has focused on the quadriceps and trunk musculature as the compartments most relevant to glucose disposal and functional mobility, respectively, and he has noted that DEXA-derived total lean mass does not distinguish between these compartments and less metabolically significant lean tissue such as skin, connective tissue, and organ mass.⁹

The resting metabolic rate argument occupies a prominent place in the muscle loss discussion and deserves careful examination. A kilogram of skeletal muscle consumes roughly 13 kcal per day at rest, which means that losing 5 kg of lean mass, as seen in the STEP 1 substudy, would reduce resting energy expenditure by approximately 65 kcal per day. This is a real number, but it is smaller than the caloric deficit produced by semaglutide or tirzepatide, which is typically in the range of 300 to 500 kcal per day, and it is also smaller than the reduction in resting metabolic rate that occurs as a result of the reduced body mass itself. The metabolic adaptation argument, while mechanistically valid, overstates the quantitative significance of muscle loss as a standalone driver of weight regain relative to the much larger effects of reduced energy intake and increased hunger signaling after weight loss.¹¹

IV · Retatrutide’s selective fat loss signal

The Phase II trial of retatrutide, published by Dr. Ania Jastreboff and colleagues in the New England Journal of Medicine in 2023, included a body composition substudy that produced results that differ qualitatively from the STEP and SURMOUNT data. Participants receiving retatrutide 12 mg lost a mean of 24.2 kg over 48 weeks, of which lean mass accounted for approximately 23% of the total weight lost. This is a lower proportion than the 30% to 40% lean mass contribution seen with semaglutide and tirzepatide, and it represents a potential signal of preferential fat loss that has generated substantial interest in the research community.¹²

The mechanism that might explain this difference lies in retatrutide’s glucagon receptor agonism, which is absent from both semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP). Glucagon, the counter-regulatory hormone to insulin, promotes hepatic amino acid uptake and gluconeogenesis, which has the effect of sparing circulating amino acids from oxidation during a caloric deficit. When amino acids are spared, the body has less need to break down skeletal muscle to mobilize amino acids for gluconeogenesis, which is one of the primary pathways through which lean tissue is lost during prolonged energy restriction. The glucagon component of retatrutide may, through this mechanism, tilt the fuel-partitioning balance toward greater reliance on adipose tissue and away from skeletal muscle during weight loss.¹³

Dr. Jastreboff and her co-authors were appropriately cautious in interpreting these results, noting that the body composition substudy was exploratory and not powered to detect differences between treatment groups on lean mass endpoints. The lower proportion of lean mass in total weight lost is a signal, not a confirmation, and the Phase III TRIUMPH program, which will enroll tens of thousands of participants, will provide the definitive body composition data on retatrutide. Nevertheless, the signal is consistent with the glucagon receptor hypothesis and suggests that future multi-receptor agonists may be able to produce weight loss with a more favorable body composition profile than the current generation of GLP-1-based therapies.

V · The evidence for protein and resistance training, plus stacking

The research on preserving lean mass during weight loss converges on two interventions that operate through different mechanisms and produce additive effects when combined. Adequate protein intake, defined as roughly 1.6 to 2.4 grams per kilogram of body weight per day during substantial caloric deficits, provides the amino acid substrate that skeletal muscle requires for protein synthesis and reduces the body’s reliance on endogenous protein stores to meet gluconeogenic demand. Progressive resistance training provides the mechanical tension signal that activates mTORC1 in skeletal muscle, which is the primary anabolic pathway that drives muscle protein synthesis and opposes the catabolic signaling that predominates during energy restriction.¹⁵

Dr. Bachmeyer has described the combination of adequate protein and resistance training as the minimum effective dose for preserving lean mass during pharmacological weight loss, and he has emphasized that protein intake alone, without the mechanical loading signal from resistance training, is insufficient because amino acid availability increases muscle protein synthesis only when the mTORC1 pathway has been primed by prior mechanical tension. Without that priming signal, excess amino acids are oxidized for energy or converted to glucose through gluconeogenesis rather than being incorporated into muscle protein. This is the molecular reason that protein intake and resistance training are complementary, not substitutable, strategies.¹⁶

The question of whether adding an anabolic peptide such as a GHRH analog plus ipamorelin to a GLP-1 receptor agonist can further attenuate lean mass loss is an active area of investigation with limited published data. The mechanistic rationale is straightforward: GH promotes protein synthesis and opposes protein catabolism in skeletal muscle, and the combination of a GHRH analog and a GHRP produces a GH pulse that could, in theory, counteract some of the catabolic signaling that occurs during the caloric deficit produced by GLP-1 receptor agonists. However, the magnitude of the GH pulse produced by this combination is smaller than the sustained GH elevation produced by exogenous GH administration, and whether it is sufficient to meaningfully shift the lean-mass-to-fat-loss ratio during GLP-1 therapy has not been demonstrated in controlled trials.¹⁸

The practical implication of the current evidence is that the most reliable approach to attenuating lean mass loss during GLP-1 receptor agonist therapy is to control the rate of weight loss and to provide the nutritional and mechanical signals that muscle requires to maintain mass. Controlling the rate of weight loss means allowing the dose titration to proceed at a pace that produces weight loss closer to 0.5% to 0.8% of body weight per week rather than 1.0% or more, which is a clinical decision that involves trading off the speed of weight loss against the preservation of lean tissue. The tradeoff is real, and the optimal balance depends on the individual’s baseline muscle mass, functional status, and metabolic goals.

VI · Putting the risk in perspective

The body composition data from the STEP and SURMOUNT programs have been available for several years now, and the research community has had time to contextualize them within the broader literature on weight loss and body composition. The conclusion that has emerged is that GLP-1 receptor agonists do not produce a pattern of lean mass loss that differs from what would be expected for weight loss of the same magnitude achieved through diet, exercise, or bariatric surgery. The lean-mass-to-total-loss ratio of 25% to 40% is consistent across weight loss modalities, which suggests that the primary driver of lean mass loss is the magnitude and rate of the energy deficit rather than a drug-specific catabolic effect.¹⁹

Dr. Gillett has framed the risk-benefit calculus in terms that are useful for clinical decision-making: the metabolic and functional risks of carrying 15 to 20 kg of excess adipose tissue, including the inflammatory, cardiovascular, and mechanical consequences of obesity, almost certainly exceed the metabolic and functional risks of losing 5 kg of lean mass in the process of losing that adipose tissue. The lean mass can be regained through resistance training after the weight loss phase is complete, whereas the cumulative metabolic damage from sustained obesity cannot be undone. This framing does not dismiss the muscle loss concern, but it places it in the context of the alternative, which is continued obesity with its own well-characterized effects on muscle quality, physical function, and metabolic health.²⁰

The retatrutide data provide a reason for optimism that future GLP-1-based therapies may produce weight loss with a more favorable body composition profile than the current generation, but the current evidence does not support the narrative that semaglutide and tirzepatide cause a uniquely problematic pattern of muscle loss. The muscle lost during therapy is real and worth addressing, and it responds to the same interventions (adequate protein and resistance training) that preserve muscle during any other form of weight loss. The question is not whether GLP-1 receptor agonists cause muscle loss. The question is whether that muscle loss is disproportionate, functionally significant, and preventable, and the evidence to date suggests that the answer is no, it can be, and yes, with the same tools that work during any other weight loss journey.